STUDY ON SELECTING THE OPTIMAL HUMECTANT IN THE DEVELOPMENT OF THE COMPOSITION AND PRODUCTION TECHNOLOGY FOR THE ORIGINAL "NEURONUCLEOS" CAPSULE FORMULATION
DOI:
https://doi.org/10.15421/jchemtech.v32i4.316480Keywords:
humectant, composition, capsules, active pharmaceutical ingredients, excipients, quality indicatorsAbstract
The influence of the composition and concentration of binders and other excipients on the physicochemical and pharmaco-technological properties of encapsulation masses, capsule quality indicators, and the "Dissolution" test was studied. The introduction of uridine-5-monophosphate disodium salt and cytidine-5-monophosphate disodium salt into the humectant solution was proposed to improve the uniformity of their distribution. The use of a solution of uridine-5-monophosphate disodium salt and cytidine-5-monophosphate disodium salt in purified water as a humectant was found to be irrational, as the resulting granulate lacked sufficient strength, was easily destroyed, and underwent significant wear. It was demonstrated that using a 10 % sorbitol solution with active pharmaceutical ingredients led to delamination of the encapsulation mass. The optimal humectant was identified as an aqueous solution containing active pharmaceutical ingredients and 5 % sorbitol. This formulation produced an encapsulation mass that was technologically suitable, exhibited good volumetric characteristics and fluidity, and had a satisfactory fractional composition. This revision improves clarity and maintains a professional tone while correcting grammar and stylistic issues.
References
Alkandari, M., Hollywood, A. (2023). People’s experiences living with peripheral neuropathy: a qualitative study. Front. Pain Res., (4), 1162405. https://doi: 10.3389/fpain.2023.1162405
Coraci, D., Romano, M., Ragazzo, L., Restivo, D. A., Cipriani, M., Gottardello, F., Pizzolato, M., Maccarone, M.C., Masiero, S. (2023). Rehabilitation of Peripheral Neuropathies: From Lexical Analysis of the Literature to Identification of Clinical Protocols. J. Clin. Med., (12), 5879. https://doi.org/10.3390/ jcm12185879
Hanewinckel, R., Oijen, M., Ikram, M. A., Doorn, P. A. (2016). The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol., (31), 5–20. https://doi 10.1007/s10654-015-0094-6
Peltier, A. C. (2022). Treatment of diabetic polyneuropathy. In M. Tavakoli (Ed.). Amsterdam, Netherlands: Elsevier.
Yang, K., Wang, Y., Chen, Y.-Li. Y., Xing, N., Lin, H., Lin H.B., Zhou, P., Yu, X. P. (2022). Progress in the treatment of diabetic peripheral neuropathy. Biomedicine Pharmacotherapy, (148), 1–10. https://doi.org/10.1016/j.biopha.2022.112717
Ziegler, D., Papanas, N., Schnell, O., Nguyen, B. D. T., Nguyen, K. T., Kulkantrakorn, K., Deerochanawong, C. (2021). Current concepts in the management of diabetic polyneuropathy. J. Diabetes. Investig., 12(4), 464–475. https://doi: 10.1111/jdi.13401
Ziegler, D., Tesfaye, S., Spallone, V., Gurieva, I., Kaabi, J.A., Mankovsky, B., Martinka, E., Radulian, G., Nguyen, K.T., Stirban, A.O., Tankova, T., Varkonyi, T., Freeman, R., Kempler, P., Boulton, A. (2022). Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Research and Clinical Practice, (186), 1–23. https://doi.org/10.1016/j.diabres.2021.109063
Rotaru, A., Târtea, G. C., Iancău, M. (2020). The Neuroprotective Role of Alpha Thioctic Acid and Vitamin B Complex in Diabetic Neuropathy - an Experimental Study. Current Health Sciences Journal, 46(2), 150–155. https://doi:10.12865/CHSJ.46.02.08
Boghdadi, M. A., Afify, H. E., N. Sabri, K. Makboul, M. (2017). Elmazar Boghdadi. Comparative Study of Vitamin B Complex Combined with Alpha Lipoic Acid versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients. Clin. Exp. Pharmacol., 7(4), 1–7. https://doi: 10.4172/2161-1459.1000241.
Manhães, M., Cesar, M., Justo, R., Geller, M., Suchmacher, M., Cisne, R., Manhães, M., Cesar, M., Justo, R., Geller, M. (2017). The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders. London, UK: IntechOpen.
Skrypko, L., Gryb, V., Skrypko, V. (2016). Efficiency of pyrimidine nucleotides in the complex treatment of patients with type 2 diabetes mellitus complicated by diabetic polyneuropathy. The Pharma Innovation Journal, 5(9), 68–71.
Seck, L. B., Basse, A., Cissé, El. H., Diedhiou, D., Touré, K., Ndiaye, M., Diop, S. N., Ndiaye, M. (2015). Efficacy and tolerance of combination of Cytidine 5 ‘ monophosphate (CMP) and Uridine-5 ‘ Triphosphate Trisodium (UTP) in patients with diabetic neuropathy: results of a study conducted in Dakar-Senegal. International Journal of Medicine and Medical Sciences, 5(8), 284–287.
Chistik, T.V. (2017).[The role of pyrimidine nucleotides in the therapy of peripheral neuropathies of different etiology (literature review)]. Mizhnarodnyi nevrolohichnyi zhurnal – International Neurological Journal, 8(94), 79–84 (in Ukrainian).
Goldberg, H., Mibielli, M.A., Nunes, C.P., Goldberg, S.W., Buchman, L., Mezitis, S.G., Rzetelna, H., Oliveira, L., Geller, M., Wajnsztajn, F. (2017). A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias. Journal of Pain Research, (10), 397–404. https://doi.: 10.2147/JPR.S123045
Fister, N. I., Oros, M. M. (2020). [The use of nucleotides in diseases of the peripheral nervous system]. Mizhnarodnyi nevrolohichnyi zhurnal – International Neurological Journal, 16(8), 33–36 (in Ukrainian) https://doi.org/10.22141/2224-0713.16.8.2020.221958
Pankiv, V. I. (2021). Treatment of neurological complications in patients with type 2 diabetes mellitus at the stage of rehabilitation after COVID-19. Mìžnarodnij endokrinologìčnij žurnal – International Journal of Endocrinology, 17(6), 491–495 (in Ukrainian). https://doi: 10.22141/2224-0721.17.6.2021.243214
Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Bookh ttps://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
State Register of Medicinal Products of Ukraine http://www.drlz.kiev.ua/.
Makarchuk, Н. R., Martyniuk, L. P. (2018). Features of the influence of keltican and polarizing light on signs of neuropathic pain in combination therapy of diabetic polyneuropathy. Рraktychna medytsyna – Рractical medicine, 8(2), 111–116 (in Ukrainian). doi: 10.22141/2224-1507.8.2.2018.137193
Rotaru, A., Albu, C. V., Tudorascu, D. R., Catalin, B., Gheonea, M., Udristoiu, I., Iancau, M. (2019) Thioctic Acid and Vitamin B Complex Improves Clinical Sings in Diabetic Peripheral Neuropathy. REV.CHIM., 70(10), 3614–3617.
Lyapunov, M., Bezugla, O., Podpruzhnikov, Y. (2012). [ST-N MOZU 42-3.0:2011. Medicinal products. Pharmaceutical development (ICH Q8). Standardization of pharmaceutical products]. Ministry of Health of Ukraine: MORION (in Ukrainian).
Almakaiev, M. S., Bashura, O. G., Sidenko, L. M. (2021). The risk assessment of the combined medicine in the capsule dosage form at the pharmaceutical development stage. Visnyk Farmatsii – Journal of Pharmacy, (102), 75–84 (in Ukrainian). https://doi.org/10.24959/nphj.21.54
European Pharmacopoeia. (2018). European Pharmacopoeia (9th ed.). Strasbourg, France: European Department for the Quality of Medicines.
State Pharmacopoeia of Ukraine: in 3 volumes. (2015). State Enterprise “Ukrainian Scientific Pharmacopoeial Center for Quality of Medicinal Products”. Kharkiv, Ukraine: State Enterprise "Ukrainian Scientific Pharmacopoeial Centre for Quality of Medicines"(in Ukrainian).
Almakaiev, M.S. (2015). Study of technological properties of active pharmaceutical ingredients for developing the combined medicine for neurofathy complex treatment. Jornal of Chemical and Pharmaceutical Research, 7(3), 1231–1235.
Almakaiev, M. S., Sidenko, L. N. (2021). Study of the physicochemical compatibility of active substances and excipients at the pharmaceutical development phase of the original drug in the form of capsules "Neuronucleos". PharmacologyOnLine, (3), 383–397.
Almakaev, M. S., Begunova, N. V. (2017). [Election of parameters of the technological process of obtaining capsules of a multicomponent drug with neurotropic action]. Farmacom – Pharmacom. (4), 23–28 (in Ukrainian).
Kafedjiiski, К. (2022). Formulation and in vitro evaluation of inosine acedoben dimepranol tablets. Pharmacia, 69(2), 319 – 325. https://doi.org/10.3897/pharmacia.69.e81442
Ponomarenko, Т. О., Dmytrievsky, D. I., Kryklyva, I. O., Hrytsenko V. I. (2023). [Substantiation of the composition and technology for obtaining combined sustained-release tablets for the treatment of hypertension]. Visnyk Farmatsii – Journal of Pharmacy, 1(105), 14–18 (in Ukrainian). https://doi.org/10.24959/nphj.23.101
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Oles Honchar Dnipro National University
This work is licensed under a Creative Commons Attribution 4.0 International License.
- Authors reserve the right of attribution for the submitted manuscript, while transferring to the Journal the right to publish the article under the Creative Commons Attribution License. This license allows free distribution of the published work under the condition of proper attribution of the original authors and the initial publication source (i.e. the Journal)
- Authors have the right to enter into separate agreements for additional non-exclusive distribution of the work in the form it was published in the Journal (such as publishing the article on the institutional website or as a part of a monograph), provided the original publication in this Journal is properly referenced
- The Journal allows and encourages online publication of the manuscripts (such as on personal web pages), even when such a manuscript is still under editorial consideration, since it allows for a productive scientific discussion and better citation dynamics (see The Effect of Open Access).
